SCHEMBL19902600

SCHEMBL19902600

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1c[nH]c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.48
NPC1 O15118 5/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
ROCK2 O75116 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
ROCK1 Q13464 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
GPR84 Q9NQS5 1/20 0.43
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
CNR2 P34972 1/20 0.42
SMYD3 Q9H7B4 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452830 0.87 ROCK2 (0.62) RAB9ANPC1HTR3EHTR3BHTR3A
SCHEMBL19902689 0.79 ROCK2 (0.46) RAB9ANPC1ROCK2ROCK1KMT2A
SCHEMBL19902458 0.79 SCN4A (0.48) NPC1HTR3AROCK2KMT2AMEN1
SCHEMBL19902713 0.78 TNKS (0.50) RAB9AHTR3AROCK2KMT2AALDH1A1
SCHEMBL19902698 0.78 ROCK2 (0.49) RAB9ANPC1ROCK2ROCK1KMT2A
SCHEMBL19710504 0.77 RAB9A (0.59) RAB9ANPC1HTR3EHTR3BHTR3A
SCHEMBL21489827 0.77 RAB9A (0.59) RAB9ANPC1HTR3EHTR3BHTR3A
SCHEMBL19902690 0.77 SMN1; SMN2 (0.44) RAB9ANPC1ROCK2L3MBTL1ROCK1
SCHEMBL26414747 0.76 RAB9A (0.76) RAB9ANPC1HTR3EHTR3BHTR3A
SCHEMBL19902696 0.76 NPC1 (0.50) RAB9ANPC1ROCK2L3MBTL1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 RAB9A 564/4885NPC1 2709/4885HTR3E 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.